{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:10:04Z","timestamp":1782601804252,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.jacl.2011.08.008","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T18:26:01Z","timestamp":1315938361000},"page":"19-26","source":"Crossref","is-referenced-by-count":20,"title":["Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity"],"prefix":"10.1016","volume":"6","author":[{"given":"Rebecca L.","family":"Attridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurajo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Koeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.08.008_bib1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/ndt\/15.12.1993","article-title":"Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?","volume":"15","author":"Broeders","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.08.008_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2004.05.040","article-title":"Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity","volume":"44","author":"Angeles","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.08.008_bib3","first-page":"39","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"Lipscombe","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jacl.2011.08.008_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2146\/ajhp070005","article-title":"Elevated serum creatinine levels associated with fenofibrate therapy","volume":"65","author":"McQuade","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacl.2011.08.008_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","article-title":"Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials","volume":"297","author":"Nissen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2011.08.008_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1592\/phco.21.13.1145.34623","article-title":"Fenofibrate-Induced elevation in serum creatinine","volume":"21","author":"Ritter","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacl.2011.08.008_bib7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.08.008_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.jacl.2011.08.008_bib9","series-title":"Antara package insert","year":"2007"},{"key":"10.1016\/j.jacl.2011.08.008_bib10","series-title":"Tricor package insert","year":"2007"},{"key":"10.1016\/j.jacl.2011.08.008_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0b013e318168e375","article-title":"An overview of drug-induced acute kidney injury","volume":"36","author":"Pannu","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jacl.2011.08.008_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/01.ccx.0000184300.68383.95","article-title":"Drug-induced acute kidney injury","volume":"11","author":"Schetz","year":"2005","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jacl.2011.08.008_bib13","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.jacl.2011.08.008_bib14","first-page":"S1","article-title":"National Kidney Foundation: K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.08.008_bib15","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2011.08.008_bib16","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.08.008_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-200767010-00013","article-title":"Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus","volume":"67","author":"Keating","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2011.08.008_bib18","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/ndt\/12.11.2244","article-title":"Preservation of renal function: the spectrum of effects by calcium-channel blockers","volume":"12","author":"Tarif","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacl.2011.08.008_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1592\/phco.25.4.491.61034","article-title":"Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease","volume":"25","author":"Bailie","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacl.2011.08.008_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.00600206","article-title":"Surrogate end points for clinical trials of kidney disease progression","volume":"1","author":"Stevens","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.08.008_bib21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/j.1552-4604.1993.tb04677.x","article-title":"Renal effects of antihypertensive medications: an overview","volume":"33","author":"Abbott","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2011.08.008_bib22","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1681\/ASN.V22s21","article-title":"The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states","volume":"2","author":"Bakris","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2011.08.008_bib23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.HYP.37.5.1268","article-title":"Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model","volume":"37","author":"Griffin","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.jacl.2011.08.008_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.RES.0000256155.31133.49","article-title":"Ca2+ channel subtypes and pharmacology in the kidney","volume":"100","author":"Hayashi","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2011.08.008_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08860220701856946","article-title":"Calcium antagonists and renal failure progression","volume":"30","author":"Robles","year":"2008","journal-title":"Ren Fail"},{"key":"10.1016\/j.jacl.2011.08.008_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00004872-199715100-00017","article-title":"Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury","volume":"15","author":"Bakris","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacl.2011.08.008_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00041552-200403000-00003","article-title":"The role of calcium antagonists in chronic kidney disease","volume":"13","author":"Gashti","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jacl.2011.08.008_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2011.08.008_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000184541.24700.c7","article-title":"Calcium antagonists: effects on cardio-renal risk in hypertensive patients","volume":"46","author":"Nathan","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jacl.2011.08.008_bib30","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/jpet.107.129197","article-title":"Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release","volume":"324","author":"Chen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jacl.2011.08.008_bib31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s002040050203","article-title":"Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid","volume":"69","author":"Wilson","year":"1995","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jacl.2011.08.008_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/sj.ki.5000180","article-title":"The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy","volume":"69","author":"Varghese","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2011.08.008_bib33","doi-asserted-by":"crossref","first-page":"H2187","DOI":"10.1152\/ajpheart.00937.2005","article-title":"PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats","volume":"290","author":"Zhao","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacl.2011.08.008_bib34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9440(10)63142-2","article-title":"A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury","volume":"164","author":"Muller","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacl.2011.08.008_bib35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.31.1.232","article-title":"Induction of P450 activity improves pressure-natriuresis in Dahl S rats","volume":"31","author":"Alonso-Galicia","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.jacl.2011.08.008_bib36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411007082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411007082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T15:56:31Z","timestamp":1638633391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411007082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1933287411007082"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.08.008","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}